1. Managing CLL With BTK Inhibitors

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Management of Treatment-Naive CLL

5. Alliance A041202 Phase 3 Trial of Ibrutinib Alone or With Rituximab

6. Alliance A Results

7. iLLUMINATE Trial Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab

8. ECOG-ACRIN E1912 Trial Ibrutinib + Rituximab vs FCR

9. ECOG-ACRIN E1912 Trial Results

10. ECOG-ACRIN E1912 Trial Results (cont)

11. Deciding When to Use Ibrutinib

12. Discussion Use of Ibrutinib

13. CLL14 Trial Venetoclax and Obinutuzumab

14. Predictors of Poor Response to Ibrutinib

15. informCLLTM Real-World Registry Prognostic Testing and Treatment Approaches in CLL

16. Acalabrutinib A Selective BTK Inhibitor

17. Acalabrutinib in Ibrutinib-Intolerant Patients

18. Next-Generation BTK Inhibitors

19. ACE-CL-001 Study Acalabrutinib in Treatment-Naive CLL/SLL

20. ACE-CL-001 Study Response Rates

21. Development of Ibrutinib Resistance in CLL

22. CAPTIVATE Trial Ibrutinib + Venetoclax in Treatment-Naive CLL/SLL

23. Using BTK Inhibitors in Clinical Practice

24. Some Ibrutinib-Associated Toxicities May Emerge After Longer-Term Use

25. Management Tips Hypertension, Atrial Fibrillation, and Bleeding

26. Toxicities Associated With Acalabrutinib

27. Dose Reductions

28. Managing Hypertension

29. Concluding Remarks

30. Abbreviations

31. Abbreviations